Clinical evaluation of Gelclair Concentrated Oral Gel

De Cordi, D, Martina, S. "Gelclair: potentially an efficacious treatment for chemotherapy-induced mucositis". Presented at the Italian Tumour League III congress for professional oncology nurses, Conegliano, Italy, 10-12 October 2001.

Study outline
• Thirty patients with chemotherapy-induced oral mucositis were evaluated for pain,
• functionality (ability to eat and drink) and grade of oral mucositis, at baseline,
• 1 day and 3 days after taking Gelclair.

Results
• Pain: 83% reported a reduction in pain, 13% remained the same and 3% showed
• initial improvement but then got worse.
• Ability to eat and drink: 83% showed distinct improvement, 7% remained the
• same, 7% got worse, while 3% reported considerable improvement followed
• by slight worsening.
• Grade of mucositis: 57% improved, 40% remained the same, 3% got worse.

Innocenti, M, Moscatelli, G, Lopez, S. "Efficacy of Gelclair in Reducing Pain in Patients with Oral Lesions - Preliminary Findings From an Open Pilot Study". Journal of Pain and Symptom Management 2002; 24(5): 456-457.

Study outline
• Thirty patients with painful lesions of the mouth and oropharynx (caused by
• various diseases) were evaluated for short-term (5-7 hours) and medium-term
• effects (7-10 days) of Gelclair on the severity of pain on swallowing and eating.

Results
• A significant reduction in pain scores was observed both in the short-term and
• medium- term following administration of Gelclair.
• In this 10 day trial, results indicated that Gelclair rapidly and effectively reduces
• pain, and can improve nutrition, associated with oral lesions
• (e.g. oral mucositis) with continued use.

Berndtson, M. "A Preliminary Study of Orassist (Gelclair) in the management of Oral Mucositis". This paper was published in Svensk Sjukhustandlakartidning (Swedish Hospital Dentistry) 2001 Nr 3 (Argang 26) pp17-21.

Study outline

• Ten patients were given Gelclair to evaluate its effect on their symptoms of
• oral mucositis.

Results
• All reported that the product was acceptable for its taste and consistency,
• and a palliative soothing effect was noted.

Full copies of papers can be obtained from Cambridge Laboratories Limited (telephone 0191 2969339).